Physician profile
Stephen P Fox
NPI 1548221328
$4,770.41
in general payments reported to CMS, 2019-2025
9 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $296 · 2021: $854 · 2022: $1,098 · 2023: $224 · 2024: $1,465 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,046 · Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,045.69 |
| Food and Beverage | $923.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,403.32 | 2019-2022 | |
| Alcon Vision LLC | $1,732.01 | 2022-2025 | Clareon, Argos, Centurion |
| Bausch & Lomb Americas INC. | $198.36 | 2022-2024 | Prolensa, Vyzulta, Envista Mx60 Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $195.01 | 2019-2021 | |
| Sight Sciences, INC. | $115.58 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Regeneron Healthcare Solutions, INC. | $62.35 | 2022-2025 | Eylea Hd, Dupixent |
| Dompe US, INC. | $30.19 | 2024 | Oxervate |
| The Cameron-Ehlen Group, INC. | $21.31 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$78,308.51 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.